Introduction
============

Influenza virus infections are associated with various neurological complications, the most common of which are seizures and encephalopathy. Encephalopathy is most frequently reported in children. Although the number of reported cases in adults has been increasing recently, the majority have been associated with influenza A (H3N2) ([@B1],[@B2]). While the emergence of influenza A (H1N1) is correlated with increased reports of neurological manifestations ([@B3]), there have been a few cases of influenza B-associated encephalopathy in adults ([@B4]). In this report, we describe the detailed clinical course of influenza B infection associated with acute encephalopathy in a healthy young man. Our discussion includes details of the brain magnetic resonance imaging (MRI) and electroencephalogram (EEG) findings.

Case Report
===========

A 19-year-old man was transferred to our emergency department after the onset of convulsions and loss of consciousness in March 2016. The patient had a medical history of febrile seizures in childhood. He had not received influenza vaccination during the season. Initially, the patient\'s body temperature had risen to 38.5℃ at home, and he had presented with convulsions and loss of consciousness 7 hours following the onset of a fever. The patient did not have a cough, nasal discharge, sore throat, headache, arthralgia, or sore muscles. In the emergency room, he appeared to be a well-developed, well-nourished man. His body temperature was 39.1℃, blood pressure was 139/68 mmHg, pulse was 96 beats/min, respiratory rate was 21 breaths/min, and oxygen saturation was 97% on room air. The Glasgow Coma Scale (GCS) score was 4 for eye opening (E), 4 for best verbal response (V), and 6 for best motor response (M). The physical examination was unremarkable, and his pupillary reflexes were normal. Neck rigidity and Kernig\'s sign were not apparent. He had a generalized convulsion lasting 1 minute in the emergency room.

The nasopharyngeal swab sample was analyzed using a rapid test kit (Quick Chaser Flu A, B; Mizuho Medy, Japan) and did not indicate the presence of either influenza A or B viral antigen. An initial laboratory examination showed a white blood cell count of 4,500 /μL (62% neutrophils), C-reactive protein level of 1.46 mg/dL, blood urea nitrogen level of 8.8 mg/dL, and creatinine level of 1.06 mg/dL. The serum interleukin (IL)-6 level was 9.06 pg/mL (normal range, \<2.41 pg/mL). Lumbar puncture was performed, and a cerebrospinal fluid analysis revealed a normal cell count (\<1 /μL), a protein level of 27.9 mg/dL, and a glucose level of 94 mg/dL. A computed tomography (CT) scan of the brain and chest radiograph showed normal findings. The anti-influenza virus treatment peramivir was started based on the information that there had been an outbreak of influenza A and B virus infections in the area during that time.

After admission, the patient\'s consciousness level worsened. He was somnolent with closed eyes. The GCS score was 12 (E2V4M6). Brain T2- and diffusion-weighted MRI on the same day showed multifocal high-signal lesions in the right parietal and frontal lobes, indicating acute encephalopathy ([Fig. 1](#g001){ref-type="fig"}). On day 2 following admission, a repeated examination of a nasopharyngeal swab sample indicated the presence of influenza B virus antigen. The patient was treated with peramivir (300 mg/day) and methylprednisolone (1,000 mg/day) for 3 days. An EEG on day 5 showed diffuse slowing of the background activity consistent with encephalopathy ([Fig. 2](#g002){ref-type="fig"}). The patient\'s physical condition gradually improved ([Fig. 3](#g003){ref-type="fig"}). The serum IL-6 level was decreased to 0.673 pg/mL on day 8. The patient was discharged without any neurological impairment on day 10 and has been followed up at an outpatient clinic. An examination showed no evidence of underlying diseases or immunodeficiency. His serum levels of immunoglobulin G, A, and M were normal. Brain MRI and EEG on day 20 following the onset showed no abnormal findings. In addition, the serum antibody titers against influenza B virus, as measured using the complement fixation test, were 1:8 on admission and 1:64 on day 20. The serum antibody titer against influenza A virus was not found to be increased at admission or throughout the clinical course.

![Brain magnetic resonance imaging on the day of admission showed multifocal high-signal lesions (arrows) in the right parietal (A: T2-weighted; B: diffusion-weighted) and frontal lobes (C: T2-weighted; D: diffusion-weighted), indicating acute encephalopathy.](1349-7235-56-1925-g001){#g001}

![Electroencephalogram on the 5th day showed diffuse slowing of the background activity, compatible with encephalopathy.](1349-7235-56-1925-g002){#g002}

![Clinical course of the patient.](1349-7235-56-1925-g003){#g003}

Discussion
==========

In this report, we describe a case of encephalopathy associated with influenza B virus infection in a previously healthy young man. To our knowledge, there have only been a few reported cases of acute encephalopathy associated with influenza B virus infection in an adult ([@B4],[@B5]). The diagnosis of influenza-associated encephalopathy requires the definitive diagnosis of an influenza virus infection and acute onset of encephalopathy, according to the diagnostic criteria of the Japanese research committee of influenza encephalopathy ([@B6]). The criteria for acute encephalopathy include severe impairment of consciousness on admission, with a GCS score of ≤10-11 or documented brain CT findings, or a sustained GCS score of ≤13 for more than 24 hours. In this case, an influenza B virus infection was diagnosed based on the rapid test kit, which confirmed an 8-fold increase in the serum levels of anti-influenza B virus antibody. Encephalopathy was diagnosed based on the sustained impaired consciousness level (GCS score of 12) and was supported by the brain MRI and EEG findings.

Goenka et al. ([@B5]) proposed the categorization of neurological manifestations of influenza, and the categories were subsequently developed by Akins et al. ([@B3]). This categorization is based on the increasing presence of neurological sequelae and mortality. The mildest is febrile seizures, followed by acute movement disorder, acute benign encephalopathy/encephalitis, and acute encephalopathy syndromes. Acute encephalopathy syndromes include mild encephalitis/encephalopathy with a reversible splenial lesion (MERS), acute necrotizing encephalopathy (ANE), acute encephalopathy with biphasic seizures and late reduced diffusion (AESD), acute infantile encephalopathy predominantly affecting the frontal lobes, acute shock with encephalopathy and multiorgan failure, and acute hemorrhagic leukoencephalopathy as the most severe type ([@B5]). Among the encephalopathy syndromes following influenza infection, MERS is clinically the most common, followed by AESD and ANE ([@B6]). Our case showed mild neurologic symptoms, including somnolence and convulsions, and MRI findings with a multifocal high signal, suggesting acute benign encephalopathy.

T2- and diffusion-weighted MRI detected a multifocal high-signal lesion in the right parietal and frontal lobes. Typical MRI findings include a lesion in the splenium of the corpus callosum in MERS patients, multiple and symmetric brain lesions affecting the bilateral thalami in ANE patients, and subcortical white matter lesions in the cerebral cortex of AESD patients ([@B3],[@B6]). The findings observed in our case were not similar to the typical findings reported for acute encephalopathy syndromes. The MRI findings suggested acute disseminated encephalomyelitis as a diagnosis; however, this was unlikely because of the negative meningeal signs and cerebrospinal fluid findings. The recovery of the MRI and EEG findings on the 20th day suggested a shorter clinical course than is usually seen with acute encephalopathy syndromes. In this sense, this case report showed unique MRI findings for benign encephalopathy associated with influenza virus infection.

The pathogenesis of influenza-associated encephalopathy remains unclear. A hyperactive cytokine response, rather than viral invasion, is believed to be responsible ([@B1],[@B7]). We found a high serum concentration of IL-6 in our patient. It was reported that the level of IL-6 is related to the disease severity and the duration of unconsciousness in patients with influenza-associated encephalopathy ([@B8],[@B9]).

Considering that the immunogenic consequence of influenza virus infection likely contributes to the pathogenesis, steroid pulse therapy is recommended as a specific therapy for influenza-associated encephalopathy ([@B10]). Indeed, our case showed dramatic improvement in consciousness following steroid therapy. Previous case reports have reported improvements in severe cases of encephalopathy following the use of corticosteroids ([@B11]). Conversely, Kawashima et al. ([@B12]), who surveyed medical doctors who had treated pediatric influenza-associated encephalopathy, showed that the administration of corticosteroids did not affect the treatment results. Therefore, a well-designed, randomized, controlled study to evaluate the effect of corticosteroid administration on influenza-associated encephalopathy is needed.

Influenza-associated encephalopathy is most frequently reported in children. Among the 25 cases from the British survey reported by Goenka et al. ([@B5]), 21 were children, and 4 were adults. Two of the adults had acute benign encephalopathy associated with influenza A (H1N1). There was a report of two cases of influenza B-associated encephalopathy in adults; they were virologically documented, with normal MRI findings and EEG findings consistent with encephalitis ([@B4]). In Japan, influenza is the most commonly identified pathogen in acute encephalopathy and is detectable by rapid detection kits for influenza infection, which are widely used among physicians. Influenza-associated encephalopathy is widely recognized in Japan, where its incidence has been estimated as 100-500 cases per year ([@B6]). The majority of patients are infants or young children aged \<5 years. [Table](#t001){ref-type="table"} shows the number of influenza B-associated encephalitis/encephalopathy cases that were reported during the influenza seasons from 2007 to 2016 in Japan ([@B13],[@B14]). According to information from the National Institute of Infectious Diseases, Japan, epidemics of influenza B occurred during the winters of 2010-2011, 2011-2012, 2013-2014, and 2015-2016 ([@B15]). [Table](#t001){ref-type="table"} shows that the number of cases of influenza B-associated encephalopathy was high in the seasons when an epidemic of influenza B occurred.

###### 

Number of Patients with Influenza B-associated Encephalitis/Encephalopathy Reported in Japan according to Season.

  Age (years)   Season                                
  ------------- -------- ---- ---- ---- ---- --- ---- -----
  0-4           7        4    7    2    8    0   22   50
  5-9           6        9    9    3    7    1   16   51
  10-19         2        1    8    3    9    0   13   36
  20-29         0        1    0    1    0    0   0    2
  30-39         0        0    2    0    0    0   2    4
  40-49         0        0    0    0    2    0   6    8
  50-59         1        0    1    0    0    1   1    4
  60-69         0        0    0    0    3    1   2    6
  70-79         0        0    0    1    0    0   1    2
  ≥80           0        0    0    0    2    2   1    5
  Total         16       15   27   10   31   5   64   168

This case report showed the detailed clinical course of encephalopathy associated with influenza B infection in an adult. The MRI and EEG findings in the acute phase were consistent with encephalopathy and returned to normal in the recovery phase. During outbreaks of influenza A and B, we suggest that physicians consider the possibility of influenza-associated encephalopathy and initiate therapy immediately for adults and children presenting with a fever and impaired consciousness.
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